Abstract
The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Current Clinical Pharmacology
Title: Inducing Synthetic Lethality using PARP Inhibitors
Volume: 5 Issue: 3
Author(s): David S. Boss, Jos H. Beijnen and Jan H.M. Schellens
Affiliation:
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Abstract: The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Export Options
About this article
Cite this article as:
S. Boss David, H. Beijnen Jos and H.M. Schellens Jan, Inducing Synthetic Lethality using PARP Inhibitors, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498798
DOI https://dx.doi.org/10.2174/157488410791498798 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease
Medicinal Chemistry Counteraction of Skin Inflammation and Aging or Cancer by Polyphenols and Flavonoids from Polypodium leucotomos and Xanthohumol
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics BSA Au Clusters as a Probe for Enhanced Fluorescence Detection Using Multipulse Excitation Scheme
Current Pharmaceutical Biotechnology Functions of the Third Intracellular Loop of the Human Melanocortin-3 Receptor
Current Pharmaceutical Design Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Opinion Paper: Promise and Pragmatism in Clinical Microbiome Research
Mini-Reviews in Medicinal Chemistry Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Preparation and Applications of Room Temperature Ionic Liquids in Organic Synthesis: A Review on Recent Efforts
Current Green Chemistry Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Meet Our Regional Editor
Current Topics in Medicinal Chemistry Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design